rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2015-78-83rsp-2042Research ArticleПРОГРЕСС В РЕВМАТОЛОГИИ В XXI ВЕКЕPROGRESS IN RHEUMATOLOGY IN THE XXI CENTURYВлияние терапии генно-инженерными биологическими препаратами на субпопуляции В-лимфоцитов при ревматических заболеваниях: новые данныеIMPACT OF THERAPY WITH BIOLOGICAL AGENTS ON B-LYMPHOCYTE SUBPOPULATIONS IN RHEUMATIC DISEASES: NEW EVIDENCEСупоницкаяЕ. ВSuponitskayaE. V.

научный сотрудник лаборатории клинической иммунологии и молекулярной биологии ревматических заболеваний ФГБНУ НИИР им. В.А. Насоновой, канд. мед. наук 

ekaterina.s@mtu-net.ruАлександроваЕ. Н.AleksandrovaE. N.

заведующая лабораторией клинической иммунологии и молекулярной биологии ревматических заболеваний ФГБНУ НИИР им. В.А. Насоновой, докт. мед. наук 

АлексанкинА. П.AleksankinA. P.

младший научный сотрудник лаборатории клинической иммунологии и молекулярной биологии ревматических заболеваний ФГБНУ НИИР им. В.А. Насоновой, канд. биол. наук 

НасоновЕ. Л.NasonovE. L.

директор ФГБНУ НИИР им. В.А. Насоновой, академик РАН, докт. мед. наук, профессор 

ФГБНУ Научно- исследовательский институт ревматологии им. В.А. Насоновой, Москва, Россия 115522 Москва, Каширское шоссе, 34АРоссияV.A. Nasonova Research Institute of Rheumatology, Moscow, Russia 34A, Kashirskoe Shosse, Moscow 115522Russian Federation2015120320155317883Copyright © Супоницкая Е.В., Александрова Е.Н., Алексанкин А.П., Насонов Е.Л., 20152015Супоницкая Е.В., Александрова Е.Н., Алексанкин А.П., Насонов Е.Л.Suponitskaya E.V., Aleksandrova E.N., Aleksankin A.P., Nasonov E.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/2042

Рассматриваются механизмы действия генно-инженерных биологических препаратов и их влияние на суб-популяции В-лимфоцитов периферической крови пациентов с системной красной волчанкой и ревматоидным артритом.

The paper considers the mechanisms of action of biological agents and their effect on peripheral blood B-lymphocyte subpopulations in patients with systemic lupus erythematosus and rheumatoid arthritis.

генно-инженерные биологические препаратысубпопуляции В-лимфоцитовревматоид- ный артритсистемная красная волчанкаbiological agentsperipheral blood B-lymphocyte subpopulationsrheumatoid arthritissystemic lupus erythematosusReferencesEdwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford). 2001;40(2):205–11. DOI: 10.1093/rheumatology/40.2.205Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford). 2001;40(2):205–11. DOI: 10.1093/rheumatology/40.2.205Kim HJ, Berek C. B cells in rheumatoid arthritis. Arthritis Res. 2000;2(2):126–31. DOI: 10.1186/ar77Kim HJ, Berek C. B cells in rheumatoid arthritis. Arthritis Res. 2000;2(2):126–31. DOI: 10.1186/ar77Metlay JP, Pure E, Steinman RM. Control of the immune response at the level of antigen-presenting cells: a comparison of the function of dendritic cells and B lymphocytes. Adv Immunol. 1989;47:45–116. DOI: 10.1016/S0065-2776(08)60662-8Metlay JP, Pure E, Steinman RM. Control of the immune response at the level of antigen-presenting cells: a comparison of the function of dendritic cells and B lymphocytes. Adv Immunol. 1989;47:45–116. DOI: 10.1016/S0065-2776(08)60662-8Takemura S, Klimiuk PA, Braun A, et al. T cell activation in rheumatoid synovium is B cell dependent. J Immunol. 2001;167(8):4710–18. DOI: 10.4049/jimmunol.167.8.4710Takemura S, Klimiuk PA, Braun A, et al. T cell activation in rheumatoid synovium is B cell dependent. J Immunol. 2001;167(8):4710–18. DOI: 10.4049/jimmunol.167.8.4710Насонов ЕЛ. Применение ритуксимаба при ревматоидном артрите. Научно-практическая ревматология. 2009;(Прил. 1):3–22 [Nasonov EL. The use of rituximab in rheumatoid arthritis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2009;(Suppl 1):3–22 (In Russ.)].Насонов ЕЛ. Применение ритуксимаба при ревматоидном артрите. Научно-практическая ревматология. 2009;(Прил. 1):3–22 [Nasonov EL. The use of rituximab in rheumatoid arthritis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2009;(Suppl 1):3–22 (In Russ.)].Samuels J, Ng YS, Coupillaud C, et al. Impaired early B cell tolerance in patients with rheumatoid arthritis. J Exp Med. 2005;201(10):1659–67. DOI: 10.1084/jem.20042321Samuels J, Ng YS, Coupillaud C, et al. Impaired early B cell tolerance in patients with rheumatoid arthritis. J Exp Med. 2005;201(10):1659–67. DOI: 10.1084/jem.20042321Anolik JH, Looney RJ, Lund FE, et al. Insights into the heterogeneity of human B cells: diverse functions, roles in autoimmunity, and use as therapeutic targets. Immunol Res. 2009;(2–3):144–58. DOI: 10.1007/s12026-009-8096-7Anolik JH, Looney RJ, Lund FE, et al. Insights into the heterogeneity of human B cells: diverse functions, roles in autoimmunity, and use as therapeutic targets. Immunol Res. 2009;(2–3):144–58. DOI: 10.1007/s12026-009-8096-7Hostmann A, Jacobi AM, Mei H, et al. Peripheral B cell abnormalities and disease activity in systemic lupus erythematosus. Lupus. 2008;17(12):1064–9. DOI: 10.1177/0961203308095138Hostmann A, Jacobi AM, Mei H, et al. Peripheral B cell abnormalities and disease activity in systemic lupus erythematosus. Lupus. 2008;17(12):1064–9. DOI: 10.1177/0961203308095138Lindenau S, Scholze S, Odendahl M, et al. Aberrant activation of B cells in patients with rheumatoid arthritis. Ann N Y Acad Sci. 2003;987:246–8. DOI: 10.1111/j.1749-6632.2003.tb06055.xLindenau S, Scholze S, Odendahl M, et al. Aberrant activation of B cells in patients with rheumatoid arthritis. Ann N Y Acad Sci. 2003;987:246–8. DOI: 10.1111/j.1749-6632.2003.tb06055.xHenneken M, Dö rner T, Burmester GR, Berek C. Differential expression of chemokine receptors on peripheral blood B cells from patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res Ther. 2005;7(5):R1001–13. DOI: 10.1186/ar1776Henneken M, Dö rner T, Burmester GR, Berek C. Differential expression of chemokine receptors on peripheral blood B cells from patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res Ther. 2005;7(5):R1001–13. DOI: 10.1186/ar1776Dö rner T, Jacobi AM, Lipsky PE. B cells in autoimmunity. Arthritis Res Ther. 2009;11(5):247. DOI: 10.1186/ar2780Dö rner T, Jacobi AM, Lipsky PE. B cells in autoimmunity. Arthritis Res Ther. 2009;11(5):247. DOI: 10.1186/ar2780Weiner GJ. Rituximab: mechanism of action. Semin Hematol. 2010;47(2):115–23. DOI: 10.1053/j.seminhematol.2010.01.011Weiner GJ. Rituximab: mechanism of action. Semin Hematol. 2010;47(2):115–23. DOI: 10.1053/j.seminhematol.2010.01.011Valentine MA, Meier KE, Rossie S, Clark EA. Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes. Regulation by protein kinase C. J Biol Chem. 1989;264(19):11282–7.Valentine MA, Meier KE, Rossie S, Clark EA. Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes. Regulation by protein kinase C. J Biol Chem. 1989;264(19):11282–7.Einfeld DA, Brown JP, Valentine MA, et al. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J. 1988;7(3):711–7.Einfeld DA, Brown JP, Valentine MA, et al. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J. 1988;7(3):711–7.Stashenko P, Nadler LM, Hardy R, et al. Characterization of a human B lymphocyte-specific antigen. J Immunol. 1980;125(4):1678–85.Stashenko P, Nadler LM, Hardy R, et al. Characterization of a human B lymphocyte-specific antigen. J Immunol. 1980;125(4):1678–85.Tedder TF, Boyd AW, Freedman AS, et al. The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. J Immunol. 1985;135(2):973–9.Tedder TF, Boyd AW, Freedman AS, et al. The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. J Immunol. 1985;135(2):973–9.Roll P, Dorner T, Tony HP. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum. 2008;58(6):1566–75. DOI: 10.1002/art.23473Roll P, Dorner T, Tony HP. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum. 2008;58(6):1566–75. DOI: 10.1002/art.23473Nakou M, Katsikas G, Sidiropoulos P, et al. Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response. Arthritis Res Ther. 2009;11(4):R131. DOI: 10.1186/ar2798Nakou M, Katsikas G, Sidiropoulos P, et al. Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response. Arthritis Res Ther. 2009;11(4):R131. DOI: 10.1186/ar2798Cambridge G, Leandro MJ, Edwards JC, et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum. 2003;48(8):2146–54. DOI: 10.1002/art.11181Cambridge G, Leandro MJ, Edwards JC, et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum. 2003;48(8):2146–54. DOI: 10.1002/art.11181Александрова ЕН, Новиков АА, Соловьев СК и др. В-клетки при аутоиммунных ревматических заболеваниях. В кн.: Анти-В-клеточная терапия в ревматологии: фокус на ритуксимаб. Под ред. ЕЛ Насонова. Москва: ИМА-Пресс; 2012. С. 8–46 [Aleksandrova EN, Novikov AA, Solov'ev SK, et al. B cells in autoimmune rheumatic diseases. In: Anti-B-kletochnaya terapiya v revmatologii: fokus na rituksimab [Anti-B-cell therapy in rheumatology: Focus on rituximab]. Nasonov EL, editor. Moscow: IMA-Press; 2012. P. 8–46.Александрова ЕН, Новиков АА, Соловьев СК и др. В-клетки при аутоиммунных ревматических заболеваниях. В кн.: Анти-В-клеточная терапия в ревматологии: фокус на ритуксимаб. Под ред. ЕЛ Насонова. Москва: ИМА-Пресс; 2012. С. 8–46 [Aleksandrova EN, Novikov AA, Solov'ev SK, et al. B cells in autoimmune rheumatic diseases. In: Anti-B-kletochnaya terapiya v revmatologii: fokus na rituksimab [Anti-B-cell therapy in rheumatology: Focus on rituximab]. Nasonov EL, editor. Moscow: IMA-Press; 2012. P. 8–46.Anolik JH, Barnard J, Owen T, et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum. 2007;56(9):3044–56. DOI: 10.1002/art.22810Anolik JH, Barnard J, Owen T, et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum. 2007;56(9):3044–56. DOI: 10.1002/art.22810Silverman GJ, Boyle DL. Understanding the mechanistic basis in rheumatoid arthritis for clinical response to anti-CD20 therapy: the B-cell roadblock hypothesis. Immunol Rev. 2008;223:175–85. DOI: 10.1111/j.1600-065X.2008.00627.xSilverman GJ, Boyle DL. Understanding the mechanistic basis in rheumatoid arthritis for clinical response to anti-CD20 therapy: the B-cell roadblock hypothesis. Immunol Rev. 2008;223:175–85. DOI: 10.1111/j.1600-065X.2008.00627.xAmu S, Tarkowski A, Dö rner T, et al. The human immunomodulatory CD25+ B cell population belongs to the memory B cell pool. Scand J Immunol. 2007;66(1):77–86. DOI: 10.1111/j.13653083.2007.01946.xAmu S, Tarkowski A, Dö rner T, et al. The human immunomodulatory CD25+ B cell population belongs to the memory B cell pool. Scand J Immunol. 2007;66(1):77–86. DOI: 10.1111/j.13653083.2007.01946.xEdwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-celltargeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350(25):2572–81. DOI: 10.1056/NEJMoa032534Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-celltargeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350(25):2572–81. DOI: 10.1056/NEJMoa032534Quartuccio L, Fabris M, Salvin S, et al. Rheumatoid factor positivity rather then ant-CCP positiviry, a lower disability and a lower number anti-TNF agents failed are associated with response to Rituximab in rheumatoid arthritis. Rheumatology (Oxford). 2009;48(12):1557–9. DOI: 10.1093/rheumatology/kep314Quartuccio L, Fabris M, Salvin S, et al. Rheumatoid factor positivity rather then ant-CCP positiviry, a lower disability and a lower number anti-TNF agents failed are associated with response to Rituximab in rheumatoid arthritis. Rheumatology (Oxford). 2009;48(12):1557–9. DOI: 10.1093/rheumatology/kep314Cornec D, Avouac J, Youinou P, Saraux A. Critical analysis of rituximab-induced serological changes in connective tissue diseases. Autoimmun Rev. 2009;8(6):515–9. DOI: 10.1016/j.autrev.2009.01.007Cornec D, Avouac J, Youinou P, Saraux A. Critical analysis of rituximab-induced serological changes in connective tissue diseases. Autoimmun Rev. 2009;8(6):515–9. DOI: 10.1016/j.autrev.2009.01.007Cambridge G, Leandro MG, Teodorescu M. B cell depletion therapy in systemic lupus erythematosus. Effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum. 2006;54(11):3612–22. DOI: 10.1002/art.22211Cambridge G, Leandro MG, Teodorescu M. B cell depletion therapy in systemic lupus erythematosus. Effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum. 2006;54(11):3612–22. DOI: 10.1002/art.22211Erre GL, Pardini S, Faedda R, Passiu G. Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature. Lupus. 2008;17(1):50–5. DOI: 10.1177/0961203307085251Erre GL, Pardini S, Faedda R, Passiu G. Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature. Lupus. 2008;17(1):50–5. DOI: 10.1177/0961203307085251Yoannou Y, Lambrianides A, Cambridge G, et al. B cell depletion therapy for patients with systemic lupus erythaematosus results in a significant drop in anticardiolipin antibody titres. Ann Rheum Dis. 2008;67(3):425–6. DOI: 10.1136/ard.2007.078402Yoannou Y, Lambrianides A, Cambridge G, et al. B cell depletion therapy for patients with systemic lupus erythaematosus results in a significant drop in anticardiolipin antibody titres. Ann Rheum Dis. 2008;67(3):425–6. DOI: 10.1136/ard.2007.078402Sanz I, Wei C, Lee FE, Anolik J. Phenotypic and functional heterogeneity of human memory B cells. Semin Immunol. 2008;20(1):67–82. DOI: 10.1016/j.smim.2007.12.006Sanz I, Wei C, Lee FE, Anolik J. Phenotypic and functional heterogeneity of human memory B cells. Semin Immunol. 2008;20(1):67–82. DOI: 10.1016/j.smim.2007.12.006Silverman GJ, Pelzek A. Rheumatoid arthritis clinical benefits from Abatacept, cytokine blockers, and Rituximab are all linked to modulation of memory B cell responses. J Rheumatol. 2014;41(5):825–8. DOI: 10.3899/jrheum.140022Silverman GJ, Pelzek A. Rheumatoid arthritis clinical benefits from Abatacept, cytokine blockers, and Rituximab are all linked to modulation of memory B cell responses. J Rheumatol. 2014;41(5):825–8. DOI: 10.3899/jrheum.140022Modi S, Soejima M, Levesque MC. The effect of targeted rheumatoid arthritis therapies on anti-citrullinated protein autoantibody levels and B cell responses. Clin Exp Immunol. 2013;173(1):8–17. DOI: 10.1111/cei.12114Modi S, Soejima M, Levesque MC. The effect of targeted rheumatoid arthritis therapies on anti-citrullinated protein autoantibody levels and B cell responses. Clin Exp Immunol. 2013;173(1):8–17. DOI: 10.1111/cei.12114Sellam J, Rouanet S, Taoufic Y, et al. Predictive factors of response to rituximab in rheumatoid arthritis with inadequate response or intolerance to anti-TNF: data from SMART trial. Ann Rheum Dis. 2010;69(Suppl 3):68 [OP0050].Sellam J, Rouanet S, Taoufic Y, et al. Predictive factors of response to rituximab in rheumatoid arthritis with inadequate response or intolerance to anti-TNF: data from SMART trial. Ann Rheum Dis. 2010;69(Suppl 3):68 [OP0050].Souto-Carneiro MM, Mahadevan V, Takada K, et al. Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor. Arthritis Res Ther. 2009(3);11:R84. DOI: 10.1186/ar2718Souto-Carneiro MM, Mahadevan V, Takada K, et al. Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor. Arthritis Res Ther. 2009(3);11:R84. DOI: 10.1186/ar2718Catalan D, Aravena O, Sabugo F, et al. B cells from rheumatoid arthritis patients show important alterations in the expression of CD86 and FcgammaRIIb, which are modulated by anti-tumor necrosis factor therapy. Arthritis Res Ther. 2010;12(2):R68. DOI: 10.1186/ar2985Catalan D, Aravena O, Sabugo F, et al. B cells from rheumatoid arthritis patients show important alterations in the expression of CD86 and FcgammaRIIb, which are modulated by anti-tumor necrosis factor therapy. Arthritis Res Ther. 2010;12(2):R68. DOI: 10.1186/ar2985Menard L, Samuels J, Ng YS, Meffre E. Inflammation-independent defective early B cell tolerance checkpoints in rheumatoid arthritis. Arthritis Rheum. 2011;63(5):1237–45. DOI: 10.1002/art.30164Menard L, Samuels J, Ng YS, Meffre E. Inflammation-independent defective early B cell tolerance checkpoints in rheumatoid arthritis. Arthritis Rheum. 2011;63(5):1237–45. DOI: 10.1002/art.30164Anolik JH, Ravikumar R, Barnard J, et al. Anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks. J Immunol. 2008;180(2):688–92. DOI: 10.4049/jimmunol.180.2.688Anolik JH, Ravikumar R, Barnard J, et al. Anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks. J Immunol. 2008;180(2):688–92. DOI: 10.4049/jimmunol.180.2.688Glaesener S, QuGlaesener S, QuDaien CI, Gailhac S, Mura T, et al. High levels of memory B cells are associated with response to a first tumor necrosis factor inhibitor in patients with rheumatoid arthritis in a longitudinal prospective study. Arthr Res Ther. 2014;16(2):R95. DOI: 10.1186/ar4543Daien CI, Gailhac S, Mura T, et al. High levels of memory B cells are associated with response to a first tumor necrosis factor inhibitor in patients with rheumatoid arthritis in a longitudinal prospective study. Arthr Res Ther. 2014;16(2):R95. DOI: 10.1186/ar4543Fonseca JE, Santos MJ, Canhao H, Choy E. Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev. 2009;8(7):538–42. DOI: 10.1016/j.autrev.2009.01.012Fonseca JE, Santos MJ, Canhao H, Choy E. Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev. 2009;8(7):538–42. DOI: 10.1016/j.autrev.2009.01.012Madhok R, Crilly A, Watson J, Capell HA. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis. 1993;52(3):232–4. DOI: 10.1136/ard.52.3.232Madhok R, Crilly A, Watson J, Capell HA. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis. 1993;52(3):232–4. DOI: 10.1136/ard.52.3.232Houssiau FA, Devogelaer JP, van Damme J, et al. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum. 1988;31(6):784–8. DOI: 10.1002/art.1780310614Houssiau FA, Devogelaer JP, van Damme J, et al. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum. 1988;31(6):784–8. DOI: 10.1002/art.1780310614Kotake S, Sato K, Kim KJ, et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res. 1996;11(1):88–95. DOI: 10.1002/jbmr.5650110113Kotake S, Sato K, Kim KJ, et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res. 1996;11(1):88–95. DOI: 10.1002/jbmr.5650110113Roll P, Muhammad K, Schumann M, et al. In vivo effects of the anti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartment. Arthritis Rheum. 2011;63(5):1255–64. DOI: 10.1002/art.30242Roll P, Muhammad K, Schumann M, et al. In vivo effects of the anti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartment. Arthritis Rheum. 2011;63(5):1255–64. DOI: 10.1002/art.30242Mahmood Z, Muhammad Kh, Roll P, et al. IL-6 receptor inhibition by Tocilizumab modulates double negative (CD19+IgDCD27-) B Cells in RA. [abstract]. Arthritis Rheum. 2012;64(10 Suppl):S754.Mahmood Z, Muhammad Kh, Roll P, et al. IL-6 receptor inhibition by Tocilizumab modulates double negative (CD19+IgDCD27-) B Cells in RA. [abstract]. Arthritis Rheum. 2012;64(10 Suppl):S754.Shirota Y, Yarboro C, Fischer R, et al. Impact of anti-interleukin6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus. Ann Rheum Dis. 2013;72(1):118–28. DOI: 10.1136/annrheumdis-2012-201310Shirota Y, Yarboro C, Fischer R, et al. Impact of anti-interleukin6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus. Ann Rheum Dis. 2013;72(1):118–28. DOI: 10.1136/annrheumdis-2012-201310Conaghan PG, Durez P, Alten RE, et al. Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial. Ann Rheum Dis. 2013;72(8):1287–94. DOI: 10.1136/annrheumdis-2012201611Conaghan PG, Durez P, Alten RE, et al. Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial. Ann Rheum Dis. 2013;72(8):1287–94. DOI: 10.1136/annrheumdis-2012201611Van Kooten C, Banchereau J. CD40-CD40 ligand. J Leuk Biol. 2000;67(1):2–17.Van Kooten C, Banchereau J. CD40-CD40 ligand. J Leuk Biol. 2000;67(1):2–17.Cutolo M, Nadler SG. Advances in CTLA-4-Ig-mediated modulation of inflammatory cell and immune response activation in rheumatoid arthritis. Autoimmun Rev. 2013;12(7):758–67. DOI: 10.1016/j.autrev.2013.01.001Cutolo M, Nadler SG. Advances in CTLA-4-Ig-mediated modulation of inflammatory cell and immune response activation in rheumatoid arthritis. Autoimmun Rev. 2013;12(7):758–67. DOI: 10.1016/j.autrev.2013.01.001Scarsi M, Paolini L, Ricotta D, et al. Abatacept reduces levels of switched memory B cells, autoantibodies, and immunoglobulins in patients with rheumatoid arthritis. J Rheumatol. 2014;41(4):666–72. DOI: 10.3899/jrheum.130905Scarsi M, Paolini L, Ricotta D, et al. Abatacept reduces levels of switched memory B cells, autoantibodies, and immunoglobulins in patients with rheumatoid arthritis. J Rheumatol. 2014;41(4):666–72. DOI: 10.3899/jrheum.130905Gottenberg JE, Ravaud P, Cantagrel A, et al. Positivity for anticyclic citrullinated peptide is associated with a better response to abatacept: data from the ‘Orencia and Rheumatoid Arthritis’ registry. Ann Rheum Dis. 2012;71(11):1815–9. DOI: 10.1136/annrheumdis-2011-201109Gottenberg JE, Ravaud P, Cantagrel A, et al. Positivity for anticyclic citrullinated peptide is associated with a better response to abatacept: data from the ‘Orencia and Rheumatoid Arthritis’ registry. Ann Rheum Dis. 2012;71(11):1815–9. DOI: 10.1136/annrheumdis-2011-201109Mackay F, Schneider P, Rennert P, Browning J. BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol. 2003;21:231–64. DOI: 10.1146/annurev.immunol.21.120601.141152Mackay F, Schneider P, Rennert P, Browning J. BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol. 2003;21:231–64. DOI: 10.1146/annurev.immunol.21.120601.141152Scholz JL, Cancro MP. Resolve, revise, and relax: the 3 Rs of B cell repertoire adjustment. Immunology Lett. 2012;143(1):2–8. DOI: 10.1016/j.imlet.2012.01.014Scholz JL, Cancro MP. Resolve, revise, and relax: the 3 Rs of B cell repertoire adjustment. Immunology Lett. 2012;143(1):2–8. DOI: 10.1016/j.imlet.2012.01.014Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009;61(9):1168–78. DOI: 10.1002/art.24699Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009;61(9):1168–78. DOI: 10.1002/art.24699Tak PP, Thurlings RM, Rossier C, et al. Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, doubleblind, placebo-controlled, dose-escalating, singleand repeateddose study. Arthritis Rheum. 2008;58(1):61–72. DOI: 10.1002/art.23178Tak PP, Thurlings RM, Rossier C, et al. Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, doubleblind, placebo-controlled, dose-escalating, singleand repeateddose study. Arthritis Rheum. 2008;58(1):61–72. DOI: 10.1002/art.23178Stohl W, Hiepe F, Latinis KM, et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in the patients with systemic lupus erythematosus. Arthritis Rheum. 2012;64(7):2328–37. DOI: 10.1002/art.34400Stohl W, Hiepe F, Latinis KM, et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in the patients with systemic lupus erythematosus. Arthritis Rheum. 2012;64(7):2328–37. DOI: 10.1002/art.34400Manzi S, Sаnchez-Guerrero J, Merrill JT, et al. BLISS-52 and BLISS-76 Study Groups: Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012;71(11):1833–8. DOI: 10.1136/annrheumdis-2011-200831Manzi S, Sаnchez-Guerrero J, Merrill JT, et al. BLISS-52 and BLISS-76 Study Groups: Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012;71(11):1833–8. DOI: 10.1136/annrheumdis-2011-200831Navarra SV, Guzmаn RM, Gallacher AE, et al. BLISS-52 Study Group: Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721–31. DOI: 10.1016/S0140-6736(10)61354-2Navarra SV, Guzmаn RM, Gallacher AE, et al. BLISS-52 Study Group: Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721–31. DOI: 10.1016/S0140-6736(10)61354-2Van Vollenhoven RF, Petri MA, Cervera R, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis. 2012;71(8):1343–9. DOI: 10.1136/annrheumdis-2011-200937Van Vollenhoven RF, Petri MA, Cervera R, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis. 2012;71(8):1343–9. DOI: 10.1136/annrheumdis-2011-200937Genovese MC, Kinnman N, de La Bourdonnaye G, et al. Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial. Arthritis Rheum. 2011;63(7):1793–803. DOI: 10.1002/art.30373Genovese MC, Kinnman N, de La Bourdonnaye G, et al. Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial. Arthritis Rheum. 2011;63(7):1793–803. DOI: 10.1002/art.30373Genovese M, Silverman J, Emery P, et al. Efficacy and safety of subcutaneous administration of tabalumab, an anti-B cell activating factor monoclonal antibody, in rheumatoid arthritis: results from a phase 3 multicenter, randomized, double-blind study [abstract]. Arthritis Rheum. 2013;65(10 Suppl):S733.Genovese M, Silverman J, Emery P, et al. Efficacy and safety of subcutaneous administration of tabalumab, an anti-B cell activating factor monoclonal antibody, in rheumatoid arthritis: results from a phase 3 multicenter, randomized, double-blind study [abstract]. Arthritis Rheum. 2013;65(10 Suppl):S733.Wang Sh-P, Iwata Sh, Nakayamada Sh, et al. Tofacitinib, a JAK inhibitor, inhibits human B cell activation in vitro. Ann Rheum Dis. 2014 Dec;73(12):2213–5. DOI:10.1136/annrheumdis-2014205615Wang Sh-P, Iwata Sh, Nakayamada Sh, et al. Tofacitinib, a JAK inhibitor, inhibits human B cell activation in vitro. Ann Rheum Dis. 2014 Dec;73(12):2213–5. DOI:10.1136/annrheumdis-2014205615Tanaka Y, Yamaoka K. JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical. Mod Rheumatol. 2013;23(3):415–24. DOI: 10.1007/s10165-012-0799-2Tanaka Y, Yamaoka K. JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical. Mod Rheumatol. 2013;23(3):415–24. DOI: 10.1007/s10165-012-0799-2Tanaka Y, Maeshima Y, Yamaoka K. In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis. Ann Rheum Dis. 2012;71(Suppl 2):i70–4. DOI: 10.1136/annrheumdis-2011200595Tanaka Y, Maeshima Y, Yamaoka K. In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis. Ann Rheum Dis. 2012;71(Suppl 2):i70–4. DOI: 10.1136/annrheumdis-2011200595

The authors declare that there are no conflicts of interest present.